Aliases & Classifications for Choreatic Disease

MalaCards integrated aliases for Choreatic Disease:

Name: Choreatic Disease 12 15 71
Chorea 12 74 53 29 6 15 71
Hereditary Chorea 12 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12859
ICD10 32 G25.5
UMLS 71 C0008489 C0699731 C4020858

Summaries for Choreatic Disease

Disease Ontology : 12 A movement disease characterized by brief, semi-directed, irregular movements that not repetitive or rhythmic, but appear to flow from one muscle to the next.

MalaCards based summary : Choreatic Disease, also known as chorea, is related to chorea, benign hereditary and chorea gravidarum, and has symptoms including ataxia, tremor and clonus. An important gene associated with Choreatic Disease is HTT (Huntingtin), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Circadian entrainment. The drugs Dopamine and Amantadine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Chorea (or choreia, occasionally) is an abnormal involuntary movement disorder, one of a group of... more...

Related Diseases for Choreatic Disease

Diseases related to Choreatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 570)
# Related Disease Score Top Affiliating Genes
1 chorea, benign hereditary 35.0 NKX2-1 ADCY5
2 chorea gravidarum 34.7 XK JRK DPYSL5
3 choreoacanthocytosis 34.2 XK VPS13A JPH3
4 huntington disease 33.1 XK VPS13A PPP1R1B JPH3 HTT DRD2
5 mcleod syndrome 33.0 XK VPS13A DRD2
6 dentatorubral-pallidoluysian atrophy 32.7 JPH3 HTT ATXN3
7 tardive dyskinesia 32.6 DRD3 DRD2
8 spinocerebellar ataxia 1 32.5 MIR9-1 HTT ATXN3
9 aceruloplasminemia 32.4 VPS13A JPH3 HTT DPYSL5 ATXN3
10 huntington disease-like 2 32.3 XK VPS13A JPH3 HTT ATXN3
11 obsessive-compulsive disorder 30.9 DRD4 DRD3 DRD2 DRD1
12 huntington disease-like 1 30.7 XK VPS13A JPH3
13 neurodegeneration with brain iron accumulation 1 30.5 XK VPS13A JPH3
14 sleep disorder 30.5 IGLON5 DRD2 ATXN3
15 autosomal dominant cerebellar ataxia 30.4 MIR9-1 JPH3 HTT ATXN3
16 neurodegeneration with brain iron accumulation 30.3 XK VPS13A JPH3
17 focal dystonia 30.3 JRK DRD5 DRD2
18 multiple system atrophy 1 30.3 HTT DRD2 ATXN3
19 tic disorder 30.3 SLC18A2 PNKD GYPE DRD5 DRD4 DRD3
20 supranuclear palsy, progressive, 1 30.3 MIR9-1 IGLON5 HTT DRD2
21 early-onset schizophrenia 30.3 DRD2 DRD1
22 mental depression 30.2 MIR9-1 DRD4 DRD2 DRD1
23 gilles de la tourette syndrome 30.2 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
24 hemidystonia 30.2 PNKD JRK GYPE
25 focal hand dystonia 30.1 JRK GYPE DRD2
26 amphetamine abuse 30.1 SLC18A2 DRD5 DRD4
27 toxic encephalopathy 30.1 SLC18A2 MIR9-1 HTT DRD2
28 avoidant personality disorder 30.1 DRD4 DRD3 DRD2
29 alcohol use disorder 30.1 DRD3 DRD2 DRD1
30 personality disorder 30.1 DRD4 DRD3 DRD2
31 attention deficit-hyperactivity disorder 30.1 SLC18A2 PPP1R1B DRD5 DRD4 DRD3 DRD2
32 migraine with or without aura 1 30.1 PNKD DRD5 DRD4 DRD3 DRD2 DRD1
33 dyskinetic cerebral palsy 30.1 PNKD NKX2-1 JRK ADCY5
34 spinocerebellar ataxia 8 30.0 JPH3 HTT ATXN3
35 lingual-facial-buccal dyskinesia 29.9 XK VPS13A JRK DRD5 DRD4 DRD3
36 mood disorder 29.8 XK SLC18A2 DRD4 DRD3 DRD2 DRD1
37 oculogyric crisis 29.7 DRD5 DRD4 DRD3 DRD2 DRD1
38 alcohol dependence 29.7 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
39 gastroparesis 29.7 DRD5 DRD4 DRD3 DRD2 DRD1
40 parkinson disease, late-onset 29.7 SLC18A2 MIR9-1 HTT DRD5 DRD4 DRD3
41 dystonia 29.6 XK VPS13A SLC18A2 PNKD NKX2-1 JPH3
42 restless legs syndrome 29.6 NKX2-1 DRD5 DRD4 DRD3 DRD2 DRD1
43 schizophrenia 29.6 SLC18A2 PPP1R1B MIR9-1 DRD5 DRD4 DRD3
44 movement disease 29.6 VPS13A SLC18A2 PNKD NKX2-1 MIR9-1 JRK
45 autism 29.3 PPP1R1B DRD5 DRD4 DRD3 DRD2 DRD1
46 autism spectrum disorder 29.3 PPP1R1B DRD5 DRD4 DRD3 DRD2 DRD1
47 bipolar disorder 29.2 SLC18A2 PPP1R1B DRD5 DRD4 DRD3 DRD2
48 sydenham chorea 12.9
49 chorea, remitting, with nystagmus and cataract 12.4
50 chorea, benign familial 12.3

Graphical network of the top 20 diseases related to Choreatic Disease:



Diseases related to Choreatic Disease

Symptoms & Phenotypes for Choreatic Disease

UMLS symptoms related to Choreatic Disease:


ataxia, tremor, clonus, myoclonus, dystonia, involuntary movements, athetosis, other symptoms involving nervous and musculoskeletal systems, muscular fasciculation, spasm, synkinesis, recurrent muscle twitches (symptom)

MGI Mouse Phenotypes related to Choreatic Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 ADCY5 ATXN3 DPYSL5 DRD1 DRD2 DRD3
2 homeostasis/metabolism MP:0005376 9.77 ADCY5 ATXN3 DRD1 DRD2 DRD3 DRD4
3 nervous system MP:0003631 9.5 ATXN3 DPYSL5 DRD1 DRD2 DRD3 DRD4

Drugs & Therapeutics for Choreatic Disease

Drugs for Choreatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Amantadine Approved Phase 4 768-94-5 2130
3
Carbidopa Approved Phase 4 28860-95-9 34359
4
Levodopa Approved Phase 4 59-92-7 6047
5
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
6 Dihydroxyphenylalanine Phase 4
7 Neurotransmitter Agents Phase 4
8 Dopamine Agents Phase 4
9 Psychotropic Drugs Phase 4
10 Analgesics Phase 4
11 Anti-Infective Agents Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Antiparkinson Agents Phase 4
14 Antiviral Agents Phase 4
15 Dopamine agonists Phase 4
16 Autonomic Agents Phase 4
17 Adjuvants, Immunologic Phase 4
18 Carbidopa, levodopa drug combination Phase 4
19 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
20 Antidepressive Agents Phase 4
21 Sympathomimetics Phase 4
22 Protective Agents Phase 4
23 Neuroprotective Agents Phase 4
24 Monoamine Oxidase Inhibitors Phase 4
25
Fluoxetine Approved, Vet_approved Phase 3 54910-89-3 3386
26
Paroxetine Approved, Investigational Phase 3 61869-08-7 43815
27
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
28
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
29
Tetrabenazine Approved, Investigational Phase 3 58-46-8 6018
30 Tranquilizing Agents Phase 3
31 Antipsychotic Agents Phase 3
32 Dopamine Antagonists Phase 3
33 Serotonin Agents Phase 3
34 Central Nervous System Depressants Phase 3
35 Cytochrome P-450 CYP2D6 Inhibitors Phase 3
36 Anti-Bacterial Agents Phase 3
37 Antiemetics Phase 3
38 Gastrointestinal Agents Phase 3
39 Tiapride Hydrochloride Phase 3
40 Serotonin Uptake Inhibitors Phase 3
41 Adrenergic Agents Phase 3
42
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
43
Citalopram Approved Phase 2 59729-33-8 2771
44
Histamine Approved, Investigational Phase 2 51-45-6 774
45
Famotidine Approved Phase 2 76824-35-6 3325
46
Trihexyphenidyl Approved Phase 2 58947-95-8, 144-11-6 5572
47
Risperidone Approved, Investigational Phase 2 106266-06-2 5073
48
Natalizumab Approved, Investigational Phase 1, Phase 2 189261-10-7
49
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
50 Excitatory Amino Acid Antagonists Phase 2

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
2 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
3 Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics Completed NCT00888186 Phase 4 levodopa/carbidopa
4 Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
5 A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea Completed NCT00219804 Phase 3 tetrabenazine or placebo
6 An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease Completed NCT01897896 Phase 3 SD-809
7 A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease Completed NCT01795859 Phase 3 SD-809;Placebo
8 Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study. Completed NCT00632645 Phase 3 Olanzapine;Xenazine;Tiapridal
9 Double-Blind, Randomised, Two-Armed Study for the Evaluation of Efficacy and Safety of Minocycline for Treatment Completed NCT00146809 Phase 3 Minocyline
10 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington's Disease Recruiting NCT04102579 Phase 3 Valbenazine;Placebo
11 A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents Recruiting NCT03813238 Phase 3 Deutetrabenazine;Placebo
12 Trial of Kuvan™ (Sapropterin) Treatment in Patients With Lesch Nyhan Disease Withdrawn NCT00935753 Phase 2, Phase 3 sapropterin
13 Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01834053 Phase 1, Phase 2
14 Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements. Completed NCT03575676 Phase 2 SOM3355 100mg BID;SOM3355 200mg BID;Placebo BID
15 NMDA-Receptor Blockade in Huntington's Chorea Completed NCT00001930 Phase 2 Amantadine
16 A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART). Completed NCT01306929 Phase 2 pridopidine
17 A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease Completed NCT02197130 Phase 2 PF-02545920;PF-02545920
18 A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD) Completed NCT00271596 Phase 2 20mg daily citalopram;Placebo
19 Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study Completed NCT00368849 Phase 2 atomoxetine;Matching Placebo
20 An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease Completed NCT01937078 Phase 2 Famotidine
21 Childhood Hypertonia of Central Origin: An Open Label Trial of Anticholinergic Treatment Effects Completed NCT00122044 Phase 2 trihexyphenidyl
22 A Trial of Prophylaxis for the PANDAS Subgroup Completed NCT00001359 Phase 2 Penicillin or Placebo
23 Risperidone for the Treatment of Huntington's Disease Chorea Not yet recruiting NCT04201834 Phase 2 Risperidone
24 Clinical and Neurochemical Effects of Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis Not yet recruiting NCT04062331 Phase 1, Phase 2 Placebos
25 A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing Chorea Terminated NCT01019473 Phase 2 AFQ056;Placebo
26 An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021 Terminated NCT02342548 Phase 2 20 mg BID of PF-02545920
27 Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD Unknown status NCT00675077 Phase 1
28 Ursodiol in Huntington's Disease Unknown status NCT00514774 Phase 1 ursodiol;placebo
29 A Phase 1b, Open-label, Parallel-group Study in Subjects With Huntington Disease to Assess the Safety, Tolerability, and Fed/Fasted Pharmacokinetics of Repeated Oral Doses of SEN0014196 Completed NCT01485965 Phase 1 SEN0014196
30 (+)-Alpha-Dihydrotetrabenazine Phase I Completed NCT02844179 Phase 1 HTBZ
31 An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients to Assess Pharmacokinetics, Candidate Pharmacodynamic Measures of Target Engagement and Disease Modulation as Well as Acute Phenotypical Effects Following Multiple Oral Doses of SEN0014196. Completed NCT01485952 Phase 1 SEN0014196 (Low Dose);SEN0014196 (High Dose);Placebo
32 The Effects of Music Therapy on Depression, Chorea and Other Symptoms of Huntington's Disease Completed NCT00178360 Phase 1
33 An Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's Disease Recruiting NCT03764215 Phase 1 Nilotinib 150 MG
34 PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease Unknown status NCT02263430
35 Exploring Hypertonia in Children With Cerebral Palsy- a Population-based Approach. Unknown status NCT01744158
36 Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases Unknown status NCT02340871
37 Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease Completed NCT01451463
38 Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea Completed NCT00615797 standard interventions penicillin VK and haloperidol
39 Characterization of Cardiac and Skeletal Myopathy, Risk Evaluation, and Phenotype-Genotype Correlation in Patients With Neuroacanthocytosis Completed NCT00007228
40 Comparative 2-D Tumor Analysis in Familial Gliomas Completed NCT00125710
41 Plasma Adiponectin Levels and Relations With Cytokines in Children With Acute Rheumatic Fever Completed NCT01886846
42 Accelerated Diffusion MRI as a Potential Image Based Biomarker for Hungtington Disease Completed NCT01884181
43 Functional Neuro-Imaging of Strategy Use During Human Behavior Completed NCT00728741
44 NIAID Clinical Center Genomics Opportunity Protocol Completed NCT02417766
45 Assessment The Effects of Proprioceptive Neuromuscular Facilitation, Myofascial Releasing Maneuvers and Home Exercises on Pain and Jaw Function in Patients With Bruxism Completed NCT03499665
46 I2PETPG - Quantification and Localisation of Imidazoline2 Binding Sites in a Group of Participants Diagnosed With Alzheimer's Disease Using 11C‑BU99008: a Positron Emission Tomography Study Completed NCT02874820 Early Phase 1 Idazoxan
47 I2PETHV - Quantification and Localisation of Imidazoline2 Binding Sites in Healthy Volunteers Using [11C]BU99008 a Positron Emission Tomography Study Completed NCT02323217 Early Phase 1 Idazoxan;Isocarboxazid
48 Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Recruiting NCT03599076
49 Prognosis of Paroxysmal Kinesigenic Choreoathetosis in Korea: a Prospective, Observational Study Recruiting NCT04023656
50 Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD): A Prospective, Randomised, Controlled, International, Multi-centre Study Recruiting NCT02535884

Search NIH Clinical Center for Choreatic Disease

Genetic Tests for Choreatic Disease

Genetic tests related to Choreatic Disease:

# Genetic test Affiliating Genes
1 Chorea 29

Anatomical Context for Choreatic Disease

MalaCards organs/tissues related to Choreatic Disease:

40
Brain, Testes, Heart, Thyroid, Globus Pallidus, Lung, Cortex

Publications for Choreatic Disease

Articles related to Choreatic Disease:

(show top 50) (show all 5525)
# Title Authors PMID Year
1
Psychosis and longitudinal outcomes in Huntington disease: the COHORT Study. 61
31611263 2020
2
Cancer-Related Fatigue: Perception of Effort or Task Failure? 61
31084200 2020
3
The spectrum of involuntary vocalizations in humans: A video atlas. 61
31651053 2019
4
How different aspects of motor dysfunction influence day-to-day function in huntington's disease. 61
31609508 2019
5
Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. 61
31613641 2019
6
Treatment of Libman-Sacks endocarditis by combination of warfarin and immunosuppressive therapy. 61
31802766 2019
7
Acute hemichorea in a young type 1 diabetic. 61
31813308 2019
8
Expression and functional characterization of missense mutations in ATP8A2 linked to severe neurological disorders. 61
31397519 2019
9
[Application of high-throughput whole genome sequencing and STR typing for the analysis of chorea villus tissue samples from spontaneous abortion]. 61
31813140 2019
10
The immunobiology of autoimmune encephalitides. 61
31611142 2019
11
Role of Phosphorylated Tau and Glucose Synthase Kinase 3 Beta in Huntington's Disease Progression. 61
31744007 2019
12
Cytosolic non-vesicular dopamine accumulation as the predominant mechanism for developing non-DOPA responsive parkinsonism in late-stage Huntington disease. 61
31466019 2019
13
HDQLIFE and Neuro-QoL Physical Function Measures: Responsiveness in Persons With Huntington's Disease. 61
31724237 2019
14
Awareness of Chorea in Huntington's Disease. 61
31707371 2019
15
[Clinical findings of a patient with hemiballism after superficial temporal artery-middle cerebral artery anastomosis for idiopathic middle cerebral artery stenosis]. 61
31761836 2019
16
A patient with McLeod syndrome showing involvement of the central sensorimotor tracts for the legs. 61
31775676 2019
17
Whole exome sequencing identifies a homozygous POLG2 missense variant in an adult patient presenting with optic atrophy, movement disorders, premature ovarian failure and mitochondrial DNA depletion. 61
31778857 2019
18
You can dance if you want to: A case of Sydenham's chorea. 61
31474378 2019
19
Huntington's chorea, a neurological disorder of all ages - Bioinformatics approach for its precise diagnosis. 61
31745395 2019
20
Cerebellar cognitive-affective syndrome preceding ataxia associated with complex extrapyramidal features in a Turkish SCA48 family. 61
31741143 2019
21
Overt Hypogonadism May Not Be a Sentinel Sign of RING Finger Protein 216: Two Novel Mutations Associated with Ataxia, Chorea, and Fertility. 61
31745488 2019
22
Coeliac disease presenting with chorea. 61
31780451 2019
23
[Chorea secondary to non-ketotic hyperglycaemia: presentation of a case]. 61
31031063 2019
24
A case of dyskinesia after levetiracetam administration. 61
31739779 2019
25
Signaling molecules targeting cannabinoid receptors: Hemopressin and related peptides. 61
31831183 2019
26
Severe Contralateral Striatal Hypometabolism in a Case of Diabetic Nonketotic Hyperglycemic Hemichorea on 18F-FDG PET/CT Brain. 61
31714279 2019
27
Discriminating chorea-acanthocytosis from Huntington's disease with single-case voxel-based morphometry analysis. 61
31704285 2019
28
Tetrabenazine Facilitates Exocytosis by Enhancing Calcium-Induced Calcium Release through Ryanodine Receptors. 61
31209099 2019
29
Clinicopathological differences between the motor onset and psychiatric onset of Huntington's disease, focusing on the nucleus accumbens. 61
31264738 2019
30
ATP8A2-related disorders as recessive cerebellar ataxia. 61
31612321 2019
31
Serum periostin levels in acute rheumatic fever: is it useful as a new biomarker? 61
31648625 2019
32
Chorea-acanthocytosis associated with two novel heterozygous mutations in the VPS13A gene. 61
31759222 2019
33
Modulation of amyloid β peptide aggregation by hydrophilic polymers. 61
31528872 2019
34
Functional movement disorders. 61
31606137 2019
35
Chorea-like symptoms and high blood concentration of ceftriaxone in a patient undergoing hemodialysis: A case report. 61
31680037 2019
36
Brain Zinc Deficiency Exacerbates Cognitive Decline in the R6/1 Model of Huntington's Disease. 61
31520307 2019
37
Handwriting Movement Abnormalities in Symptomatic and Premanifest Huntington's Disease. 61
31538093 2019
38
Selection on VPS13A linked to migration in a songbird. 61
31451666 2019
39
The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families. 61
31571321 2019
40
[Classification, differential diagnoses and therapy in patients with chorea]. 61
31461823 2019
41
[CHOREA GRAVIDARUM: CASE REPORT AND REVIEW OF THE LITERATURE]. 61
31738489 2019
42
Treatment of Chorea in Childhood. 61
31604647 2019
43
Hyperkinetic movement disorders in congenital disorders of glycosylation. 61
31132195 2019
44
ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. 61
31538084 2019
45
Efficacy of ethyl-EPA as a treatment for Huntington disease: a systematic review and meta-analysis. 61
30890195 2019
46
Chorea. 61
31356291 2019
47
Cyclin-Dependent Kinase 5 Dysfunction Contributes to Depressive-like Behaviors in Huntington's Disease by Altering the DARPP-32 Phosphorylation Status in the Nucleus Accumbens. 61
31060804 2019
48
Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders. 61
31236685 2019
49
Spinocerebellar ataxia 48 presenting with ataxia associated with cognitive, psychiatric, and extrapyramidal features: A report of two Italian families. 61
31126790 2019
50
VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications. 61
29455579 2019

Variations for Choreatic Disease

Expression for Choreatic Disease

Search GEO for disease gene expression data for Choreatic Disease.

Pathways for Choreatic Disease

Pathways related to Choreatic Disease according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 PPP1R1B DRD5 DRD4 DRD3 DRD2 DRD1
2
Show member pathways
12.43 SLC18A2 PPP1R1B DRD5 DRD4 DRD3 DRD2
3 12.21 PPP1R1B DRD5 DRD2 DRD1 ADCY5
5
Show member pathways
12.05 PPP1R1B DRD5 DRD4 DRD2 DRD1
6
Show member pathways
11.87 SLC18A2 PPP1R1B DRD2 DRD1 ADCY5
7 11.86 PPP1R1B DRD5 DRD4 DRD3 DRD2 DRD1
8
Show member pathways
11.81 DRD5 DRD4 DRD3 DRD2 DRD1
9
Show member pathways
11.73 SLC18A2 PPP1R1B DRD4 DRD3 DRD2
10
Show member pathways
11.66 PPP1R1B DRD1 ADCY5
11 11.63 DRD2 DRD1 ADCY5
12 10.9 DRD5 DRD3 DRD2 DRD1
13
Show member pathways
10.46 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1

GO Terms for Choreatic Disease

Cellular components related to Choreatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 SLC18A2 GYPE DRD5 DRD4 DRD3 DRD2
2 dendrite GO:0030425 9.83 HTT DRD4 DRD2 DRD1 DPYSL5
3 glutamatergic synapse GO:0098978 9.72 PPP1R1B DRD4 DRD3 DRD2 DRD1
4 synaptic vesicle membrane GO:0030672 9.63 SLC18A2 DRD3 DRD2
5 GABA-ergic synapse GO:0098982 9.58 DRD3 DRD2 DRD1
6 ciliary membrane GO:0060170 9.54 DRD5 DRD2 DRD1
7 non-motile cilium GO:0097730 9.33 DRD5 DRD2 DRD1
8 cell GO:0005623 9.32 XK VPS13A JPH3 HTT DRD5 DRD4
9 dopaminergic synapse GO:0098691 9.13 SLC18A2 DRD3 DRD2

Biological processes related to Choreatic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.99 SLC18A2 DRD5 DRD4 ATXN3
2 cellular calcium ion homeostasis GO:0006874 9.91 XK DRD5 DRD4 DRD3
3 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.89 DRD5 DRD1 ADCY5
4 response to toxic substance GO:0009636 9.88 SLC18A2 DRD3 DRD2
5 memory GO:0007613 9.87 PPP1R1B JPH3 DRD1
6 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.86 DRD5 DRD3 DRD2 DRD1
7 learning GO:0007612 9.85 JPH3 DRD3 DRD1
8 social behavior GO:0035176 9.84 VPS13A DRD4 DRD3
9 visual learning GO:0008542 9.84 PPP1R1B DRD3 DRD2 DRD1
10 activation of adenylate cyclase activity GO:0007190 9.83 DRD5 DRD1 ADCY5
11 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.82 DRD3 DRD2 DRD1
12 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.81 DRD5 DRD3 DRD2 DRD1
13 associative learning GO:0008306 9.8 DRD5 DRD2 DRD1
14 response to morphine GO:0043278 9.8 PPP1R1B DRD3 DRD2
15 negative regulation of blood pressure GO:0045776 9.79 DRD5 DRD3 DRD2
16 dopamine receptor signaling pathway GO:0007212 9.78 DRD4 DRD3 DRD2 DRD1
17 arachidonic acid secretion GO:0050482 9.77 DRD4 DRD3 DRD2
18 negative regulation of protein secretion GO:0050709 9.77 DRD4 DRD3 DRD2
19 response to cocaine GO:0042220 9.77 PPP1R1B DRD5 DRD3 DRD2 DRD1
20 negative regulation of voltage-gated calcium channel activity GO:1901386 9.76 DRD4 DRD3 DRD2
21 dopamine metabolic process GO:0042417 9.76 DRD4 DRD3 DRD2 DRD1
22 prepulse inhibition GO:0060134 9.75 DRD3 DRD2 DRD1
23 behavioral response to ethanol GO:0048149 9.74 DRD4 DRD3 DRD2
24 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.73 DRD5 DRD3 DRD2 DRD1
25 temperature homeostasis GO:0001659 9.72 DRD2 DRD1
26 negative regulation of cytosolic calcium ion concentration GO:0051481 9.72 DRD3 DRD2
27 regulation of dopamine metabolic process GO:0042053 9.72 PNKD DRD4 DRD1
28 transmission of nerve impulse GO:0019226 9.71 DRD5 DRD1
29 long-term synaptic depression GO:0060292 9.71 DRD5 DRD1
30 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.71 DRD3 DRD2
31 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.71 DRD5 DRD3 DRD1 ADCY5
32 positive regulation of renal sodium excretion GO:0035815 9.7 DRD3 DRD2
33 grooming behavior GO:0007625 9.7 DRD2 DRD1
34 G protein-coupled receptor internalization GO:0002031 9.7 DRD3 DRD2
35 striatum development GO:0021756 9.7 DRD2 DRD1
36 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.7 DRD3 DRD2 DRD1
37 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.69 DRD4 DRD3
38 regulation of potassium ion transport GO:0043266 9.68 DRD3 DRD2
39 peristalsis GO:0030432 9.68 DRD2 DRD1
40 mating behavior GO:0007617 9.68 DRD5 DRD1
41 cellular response to catecholamine stimulus GO:0071870 9.67 DRD5 DRD1
42 cerebral cortex GABAergic interneuron migration GO:0021853 9.67 DRD2 DRD1
43 dopamine transport GO:0015872 9.67 SLC18A2 DRD1
44 response to histamine GO:0034776 9.67 DRD4 DRD3 DRD2
45 negative regulation of dopamine receptor signaling pathway GO:0060160 9.65 DRD3 DRD2
46 regulation of neurotransmitter uptake GO:0051580 9.65 DRD3 DRD2
47 behavioral response to cocaine GO:0048148 9.65 PPP1R1B DRD4 DRD3 DRD2 DRD1
48 regulation of locomotion involved in locomotory behavior GO:0090325 9.64 DRD3 DRD2
49 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.64 DRD4 DRD2
50 acid secretion GO:0046717 9.63 DRD3 DRD2

Molecular functions related to Choreatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.58 DRD4 DRD3 DRD2
2 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD4 DRD3 DRD2
4 D1 dopamine receptor binding GO:0031748 9.37 PPP1R1B DRD3
5 dopamine binding GO:0035240 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
6 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.32 DRD5 DRD1
7 dopamine neurotransmitter receptor activity GO:0004952 9.02 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Choreatic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....